AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00851968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pringle's Maneuver
Description: The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
Study NCT04497181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Coil embolization surgery
Description: Embolization of aneurysms with various coils system
Study NCT04497181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coil embolization surgery
Description: Embolization of aneurysms with various coils system
Study NCT01413581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBSSL (recombinant human bile-salt-stimulated lipase)
Description: rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
Study NCT01413581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
Study NCT00408070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: cycle 2 (6 cycles re-evaluated and follow up)
Study NCT00408070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: cycle #1 and continuous through entire regimen; treated every 3 weeks
Study NCT00408070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: cycle #1 and continuous through entire regimen; treated every 3 weeks
Study NCT01281501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 10 ml of 0.9% sodium chloride solution
Study NCT01281501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 80 mg of intravenous pantoprazole
Study NCT01281501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antacid
Description: 30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
Study NCT01281501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antacid
Description: 30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
Study NCT01281501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butylbromide
Description: 20 mg of intravenous hyoscine butylbromide
Study NCT01281501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Description: 20 mg of intravenous hyoscine butylbromide
Study NCT00807196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250mg/m2 day -21 and day -14 of preparative regimen
Study NCT00807196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y ibritumomab tiuxetan (Zevalin)
Description: 0.4 mCi/kg IV on day -14 of preparative regimen
Study NCT00807196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Study NCT00807196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
Study NCT03336970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHX
Study NCT00807196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non myeloablative allogeneic stem cell transplantation
Description: Blood stem cell infusion on day 0
Study NCT01624584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Description: six sessions of child anxiety treatment
Study NCT01624584 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment
Description: six sessions of treatment consistent with current practice
Study NCT01147497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
Study NCT01147497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
Study NCT04142645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiMEDs
Description: The OptiMEDs intervention is a multi-faceted intervention combining:~1. an ICT platform:~   * automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~  * a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~  * an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~2. a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses.
Study NCT03336970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Study NCT03965585 — intervention group
Intervention type: PROCEDURE
Intervention: in-office hysteroscopy
Description: in-office hysteroscopy with miniaturized instruments
Study NCT04189523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC Pain Management
Description: Study subjects will be compared to historical controls selected for same age +/- 5yrs, gender, fracture type who meet the inclusion criteria and do not have historical documentation of one of the exclusion criteria. Controls will be identified by the ICD-10 injury codes selected for use in this study. Clinical course and pain management data will be collected through the EMR only.
Study NCT04189523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early US Guided Nerve Block Administration
Description: US-Guided regional anesthesia (fascia illiaca compartment block or brachial plexus block)
Study NCT04130087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selegiline Hydrochloride 10 MG
Description: Single 10mg tablet of Selegiline Hydrochloride
Study NCT00851968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemihepatic vascular Clamping
Description: The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
Study NCT00851968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal vein occlusion
Description: The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
Study NCT02603965 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 TP3805
Description: Given IV
Study NCT02603965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
Study NCT02603965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
Study NCT02603965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT02603965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02051699 — intervention group
Intervention type: PROCEDURE
Intervention: radiographic of standing knee
Description: the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
Study NCT03707028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Film-coated tablet
Study NCT03707028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution administered intravenously
Study NCT03676101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV Recombinant Vaccine
Description: Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
Study NCT03676101 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
Study NCT03395119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
Study NCT02347631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye
Description: Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the trial. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this experimental arm, Alcon Dailies Total 1 lenses will be worn first.
Study NCT01936194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA+EPA
Study NCT01936194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High Olive Oil
Study NCT02347631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.
Description: Soft contact lens - Daily wear disposable lens to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over study where both brands of lenses will be worn by each participant over the course of the study. Participants will be randomized for the order in which the two brands of lenses will be worn. There is a washout period of one month in between each 2 month contact lens wearing period.~In this active comparator arm, Acuvue TruEye lenses will be worn first.
Study NCT01219842 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INVASIVE (INV) treatment
Description: Modern endovascular and/or open revascularisation according to the TASC II recommendations.
Study NCT01219842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment (BMT)
Description: Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
Study NCT00948740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D (ergocalciferol)
Description: The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
Study NCT00848744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study NCT00848744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
Study NCT04874857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia, Rosmarinus officinalis L. and Origanum majorana L.
Description: Massage application
Study NCT04874857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby oil
Description: Massage application
Study NCT03846245 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04130087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Placebo Tablet, identical appearance to experimental tablet.
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron - Single Dose
Description: 0.25 mg by vein for 1 dose (day 0).
Study NCT03792048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Compressive Anastomosis
Description: A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
Study NCT01936194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron - Triple Dose
Description: 0.25 mg by vein for 3 doses (days 0, 2, 4).
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
Study NCT03395119 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ozone
Description: After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
Study NCT03395119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: 3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver >60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
Study NCT03395119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: 3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
Study NCT03467152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irsenontrine
Description: Oral hypromellose capsules.
Study NCT03467152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral hypromellose capsules.
Study NCT03872492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Assessment on mobile
Description: The digital assessment is composed on 5 tests:~* My daily survey~* My evaluation~* My cognition~* My emotions~* My voice~Data will also be collected passively.
Study NCT02899169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Realgar-Indigo naturalis formula
Study NCT03199443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EMG pelvic floor
Description: EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
Study NCT03739229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
Study NCT03739229 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
Study NCT03739229 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H7N9 LAIV
Description: 2 intranasal administrations of H7N9 live influenza vaccine
Study NCT03739229 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H7N9 LAIV
Description: 2 intranasal administrations of H7N9 live influenza vaccine
Study NCT03721029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative nerve monitoring,
Description: Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
Study NCT03721029 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care robotic-assisted radical prostatectomy
Description: With out the usage of intraoperative nerve monitoring
Study NCT02230488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Diabetes Case Management
Description: A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~--------------------------------------------------------------------------------
Study NCT01811667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study NCT02819778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: usual care
Study NCT02819778 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: S100B
Study NCT04246931 — intervention group
Intervention type: OTHER
Intervention: No intervention (survey)
Description: No intervention -> survey at 1 timepoint
Study NCT02899169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: all-trans retinoic acid
Study NCT02899169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Study NCT01510288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX and ipilimumab
Description: All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
Study NCT02226133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAAx, Inc. TigerPaw® System II
Description: Exclusion of Left Atrial Appendage.
Study NCT04269382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Combined non-invasive intermittent (oscillometric arm cuff), non-invasive continuous (finger cuff and ClearSight device), and invasive continuous (intra-arterial catheter) BP measurements
Description: Continuous (finger cuff) noninvasive and invasive BP measurements, over a 30-min period. Pairs of noninvasive/invasive BP recorded each minute). In the same time, 3 pairs of oscillometric NIBP (cuff placed around a calf), and invasive BP measurements, at 30-sec intervals. The cuff is then placed around an arm and triplets of BP (arm cuff, finger cuff, intra-arterial catheter) will be taken over a 20-min period, at 3-min intervals and every time the invasive and/or the continuous finger cuff measurements cross the threshold of 65 mmHg for the mean BP. If clinically indicated, a cardiovascular intervention that can be either vascular volume expansion or initiation of vasoactive drug therapy, can be administered during this period. Finally, the cuff placed around the arm will be once again placed around the calf to take 3 pairs of oscillometric NIBP measurement with cuff placed around a calf, and simultaneous invasive BP measurement, at 30-second intervals.
Study NCT01100957 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal intubation with a single use flexible videoscope
Description: tracheal intubation with a single use flexible videoscope
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide chemotherapy (AI)
Description: Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
Study NCT01100957 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tracheal intubation with a single use flexible videoscope
Description: tracheal intubation with a single use flexible videoscope
Study NCT02523469 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Study NCT02899169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arsenic trioxide
Study NCT02899169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Study NCT02899169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Study NCT04354428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic Acid
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinecard
Description: 750 mg/m2 as an IV bolus.
Study NCT00410488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesna
Description: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).